EP1100779A1 - Indolinones substituees, leur production et leur utilisation comme medicaments - Google Patents

Indolinones substituees, leur production et leur utilisation comme medicaments

Info

Publication number
EP1100779A1
EP1100779A1 EP99926454A EP99926454A EP1100779A1 EP 1100779 A1 EP1100779 A1 EP 1100779A1 EP 99926454 A EP99926454 A EP 99926454A EP 99926454 A EP99926454 A EP 99926454A EP 1100779 A1 EP1100779 A1 EP 1100779A1
Authority
EP
European Patent Office
Prior art keywords
group
methyl
substituted
alkyl
indolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99926454A
Other languages
German (de)
English (en)
Inventor
Armin Heckel
Rainer Walter
Wolfgang Grell
Jacobus C. A. Van Meel
Norbert Redemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1100779A1 publication Critical patent/EP1100779A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Abstract

La présente invention concerne des indolinones substituées correspondant à la formule générale (I), dans laquelle les groupes R1 à R5 et X correspondent à la définition donnée dans la revendication 1, leurs isomères et leurs sels, en particulier leurs sels physiologiquement compatibles, qui présentent des caractéristiques pharmacologiques précieuses, en particulier un effet inhibiteur sur différentes kinases et sur différents complexes cycline/CDK, ainsi que sur la prolifération de différentes cellules tumorales, des médicaments contenant ces composés, leur utilisation et leur procédé de production.
EP99926454A 1998-06-04 1999-05-28 Indolinones substituees, leur production et leur utilisation comme medicaments Withdrawn EP1100779A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19824922 1998-06-04
DE19824922A DE19824922A1 (de) 1998-06-04 1998-06-04 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP1999/003692 WO1999062882A1 (fr) 1998-06-04 1999-05-28 Indolinones substituees, leur production et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
EP1100779A1 true EP1100779A1 (fr) 2001-05-23

Family

ID=7869856

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99926454A Withdrawn EP1100779A1 (fr) 1998-06-04 1999-05-28 Indolinones substituees, leur production et leur utilisation comme medicaments

Country Status (23)

Country Link
EP (1) EP1100779A1 (fr)
JP (1) JP2002516906A (fr)
KR (1) KR20010043973A (fr)
CN (1) CN1303374A (fr)
AU (1) AU764782B2 (fr)
BG (1) BG104938A (fr)
BR (1) BR9910898A (fr)
CA (1) CA2328291A1 (fr)
CO (1) CO5050294A1 (fr)
DE (1) DE19824922A1 (fr)
EA (1) EA003514B1 (fr)
EE (1) EE200000723A (fr)
HR (1) HRP20000831A2 (fr)
HU (1) HUP0102210A3 (fr)
ID (1) ID27035A (fr)
IL (1) IL138702A0 (fr)
NO (1) NO20006138L (fr)
PL (1) PL344467A1 (fr)
SK (1) SK18222000A3 (fr)
TR (1) TR200003515T2 (fr)
WO (1) WO1999062882A1 (fr)
YU (1) YU73900A (fr)
ZA (1) ZA200005435B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
JP2004508366A (ja) * 2000-09-01 2004-03-18 グラクソ　グループ　リミテッド オキシインドール誘導体
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2004537537A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
JP2004536097A (ja) * 2001-06-29 2004-12-02 アブ サイエンス 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
US6765012B2 (en) 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
DE102004012070A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101547892B (zh) * 2006-12-05 2014-08-20 艾尼纳制药公司 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
CN101735071A (zh) * 2009-12-04 2010-06-16 大连凯飞精细化工有限公司 一种生产4-n,n-二甲胺基甲基苯胺的方法
CN103102352B (zh) * 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
GB201208775D0 (en) 2012-05-18 2012-07-04 Uni I Oslo Chemical compounds
CN103848814B (zh) * 2012-12-06 2016-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的取代吲哚满酮衍生物
WO2024050297A1 (fr) * 2022-09-02 2024-03-07 Deciphera Pharmaceuticals, Llc Inhibiteurs d'ulk et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE838623A (fr) * 1976-02-16 1976-06-16 Derives de 3-hydroxymethylene-2-indolinone et procede pour leur production
US4145422A (en) * 1977-09-06 1979-03-20 Abbott Laboratories Aminomethylene oxindoles
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9962882A1 *

Also Published As

Publication number Publication date
TR200003515T2 (tr) 2001-06-21
NO20006138L (no) 2001-02-01
CN1303374A (zh) 2001-07-11
JP2002516906A (ja) 2002-06-11
IL138702A0 (en) 2001-10-31
ZA200005435B (en) 2002-01-07
HRP20000831A2 (en) 2001-12-31
CA2328291A1 (fr) 1999-12-09
EA003514B1 (ru) 2003-06-26
ID27035A (id) 2001-02-22
EE200000723A (et) 2002-04-15
AU4370799A (en) 1999-12-20
YU73900A (sh) 2003-04-30
HUP0102210A2 (hu) 2001-11-28
CO5050294A1 (es) 2001-06-27
BR9910898A (pt) 2001-02-13
SK18222000A3 (sk) 2001-08-06
KR20010043973A (ko) 2001-05-25
BG104938A (en) 2001-06-29
NO20006138D0 (no) 2000-12-01
DE19824922A1 (de) 1999-12-09
WO1999062882A1 (fr) 1999-12-09
AU764782B2 (en) 2003-08-28
EA200100001A1 (ru) 2001-08-27
PL344467A1 (en) 2001-11-05
HUP0102210A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
EP1071665B1 (fr) Indolinones substituees a effet inhibiteur sur des kinases et des complexes cycline/cdk
EP1100779A1 (fr) Indolinones substituees, leur production et leur utilisation comme medicaments
EP1224170B1 (fr) Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments
EP1212318B1 (fr) Indolinones substituees utilisees comme inhibiteurs de la tyrosine kinase
EP1115704B1 (fr) Nouvelles indolinones substituees a effet inhibiteur sur differentes kinases et differents complexes cycline/cdk
DE19924401A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001027080A2 (fr) Indolinones substituees en position 5, leur production et leur utilisation comme medicament
US6169106B1 (en) Indolinones having kinase inhibitory activity
EP1379501A1 (fr) Indolinones substituees en position 6 et leur utilisation comme inhibiteurs de kinase
US6545035B1 (en) Substituted indolinones with kinase inhibitory activity
DE19844003A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19940829A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10042696A1 (de) In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19949208A1 (de) In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10029285A1 (de) Neue substituierte Indolinone,ihre Herstellung und ihre Verwendung als Arzneimittel
CZ20004520A3 (cs) Substituované indolinony, způsob jejich výroby a jejich použití
DE19937496A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CZ20003788A3 (cs) Substituované indolinony

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20010104;LV PAYMENT 20010104;RO PAYMENT 20010104;SI PAYMENT 20010104

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG

17Q First examination report despatched

Effective date: 20030929

17Q First examination report despatched

Effective date: 20030929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061201